Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement

• Published in: Frontiers in endocrinology (Lausanne) Vol. 12; p. 739875
• Main Authors: Huang, Zhimin, Ng, Kaka, Chen, Hongyan, Deng, Wanping, Li, Yanbing
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 31.01.2022
• Subjects: Biomarkers; Body Mass Index; controlled attenuation parameter (CAP); diabetes mellitus; Elasticity Imaging Techniques; Endocrinology; Female; FibroScan; Humans; insulin resistance; Male; Metabolic Diseases - diagnostic imaging; metabolic syndrome (MetS); Metabolic Syndrome - diagnostic imaging; Middle Aged; non-alcoholic fatty liver disease (NAFLD); Non-alcoholic Fatty Liver Disease - diagnostic imaging; non-alcoholic fatty liver disease (NAFLD); FibroScan; diabetes mellitus; controlled attenuation parameter (CAP); metabolic syndrome (MetS); insulin resistance

Renaming non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated fatty liver disease (MAFLD) suggests a shift of emphasis to the accompanying metabolic disturbance. Controlled attenuation parameter (CAP) measured by FibroScan has been shown to be correlated with hepatic steatos...